Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dx Assays Opens R&D Lab As Singapore’s First Developer Of Molecular Diagnostic Assays

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Dx Assays, Singapore's first commercial developer of molecular diagnostic assays, opened its new R&D center in Singapore Sept. 8

You may also be interested in...



Singapore’s Dx Assay Pushing Fee-for-service Model In Companion Diagnostics

Dx assays Pte. Ltd. says its fee-for-service business model makes it a unique provider of companion diagnostics in a market set to boom globally as U.S. FDA and other regulators push for drug firms to develop diagnostics alongside drugs.

As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups

SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions

As Asia Gets Richer, Singapore's EDB Turns Investments To Tech-enabled, Remote Monitoring Start-Ups

SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions

Related Content

UsernamePublicRestriction

Register

SC069551

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel